Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord

Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord

Abstract Background Diabetic neuropathic pain (DNP) is a common and distressing complication in patients with diabetes, and the underlying mechanism remains unclear. Tricyclic antidepressants (TCAs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are recommended as first-line drugs for...

Full description

Bibliographic Details
Main Authors: Ting-Ting Zhang, Rui Xue, Shi-Yong Fan, Qiong-Yin Fan, Lei An, Juan Li, Lei Zhu, Yu-Hua Ran, Li-Ming Zhang, Bo-Hua Zhong, Yun-Feng Li, Cai-Ying Ye, You-Zhi Zhang
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Journal of Neuroinflammation
Subjects:
Ammoxetine
SNRI
Diabetic neuropathic pain
Glia
Cytokines
Mitogen-activated protein kinase
Online Access:http://link.springer.com/article/10.1186/s12974-018-1216-3

Internet

http://link.springer.com/article/10.1186/s12974-018-1216-3

Similar Items